Smac Co. Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
November 12, 2021 at 02:26 am EST
Share
Smac Co. Ltd. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was KRW 298.39 million compared to KRW 230.26 million a year ago. Net loss was KRW 6,319.18 million compared to KRW 3,756.74 million a year ago. Basic loss per share from continuing operations was KRW 115 compared to KRW 70 a year ago. Diluted loss per share from continuing operations was KRW 115 compared to KRW 70 a year ago. Basic loss per share was KRW 115 compared to KRW 70 a year ago.
For the nine months, sales was KRW 993.59 million compared to KRW 1,147.15 million a year ago. Net loss was KRW 7,473.01 million compared to net income of KRW 36,491.03 million a year ago. Basic loss per share from continuing operations was KRW 135 compared to basic earnings per share from continuing operations of KRW 705 a year ago. Diluted loss per share from continuing operations was KRW 135 compared to diluted earnings per share from continuing operations of KRW 705 a year ago. Basic loss per share was KRW 135 compared to basic earnings per share of KRW 705 a year ago.
Eco Volt Co Ltd, formerly S-MAC Co Ltd, is a Korea-based company engaged in the manufacture of mobile phone modules. The Company operates its business through six segments. Manufacturing and Sales of Antistatic Products and Plastic Films segment is engaged in the manufacture and sale of antistatic products and plastic films. Manufacture and Sales of Automotive Light Bulbs and Electric Devices segment engages in the manufacture and sale of automotive light bulbs and electric devices. Manufacturing and Sales of Touch Screen Modules segment is engaged in the manufacturing and sale of touch screen modules. New Technology Finance Business segment engages in the new technology finance business. Research, Development, and Technology Transfer of Diagnostic Raw Material Antibodies and Diagnostic Kits segment engages in the Research, development, and technology transfer of diagnostic raw material antibodies and others. Pharmaceutical Wholesalers segment engages in the Pharmaceutical business.